Laman UtamaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$6.78
Julat hari
$6.23 - $7.60
Julat tahun
$3.32 - $12.70
Permodalan pasaran
234.39J USD
Bilangan Purata
20.79K
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(CHF) | Jun 2024info | Perubahan T/T |
---|---|---|
Hasil | 1.55J | 273.73% |
Perbelanjaan pengendalian | 4.44J | -4.84% |
Pendapatan bersih | -15.08J | 5.66% |
Margin untung bersih | -972.40 | 74.76% |
Pendapatan bagi setiap syer | — | — |
EBITDA | -15.37J | -0.62% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(CHF) | Jun 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 159.13J | -27.07% |
Jumlah aset | 170.62J | -25.98% |
Jumlah liabiliti | 15.05J | -38.62% |
Jumlah ekuiti | 155.57J | — |
Syer tertunggak | 33.18J | — |
Harga kepada buku | 1.45 | — |
Pulangan pada aset | -22.42% | — |
Pulangan pada modal | -24.17% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(CHF) | Jun 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -15.08J | 5.66% |
Tunai daripada operasi | -15.72J | -18.38% |
Tunai daripada pelaburan | 13.15J | 225.87% |
Tunai daripada pembiayaan | -267.00K | 2.55% |
Perubahan bersih dalam tunai | -2.66J | 75.12% |
Aliran tunai bebas | -9.80J | -15.75% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in ZĂĽrich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
162